These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20028267)

  • 1. Re: Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis.
    Lane SS; Stroman DW; Cockrum P
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):571; author reply 573-5. PubMed ID: 20028267
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis.
    Mack RJ; Shott S; Schatz S; Farley SJ
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):279-84. PubMed ID: 19348601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.
    Walter K; Tyler ME
    Cornea; 2006 Aug; 25(7):855-7. PubMed ID: 17068466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3% treatment on corneal wound healing in pigmented rabbits following anterior keratectomy.
    Williams KK; McCartney MD; Rice RL; Wax MB; Hiddemen JW
    Vet Ophthalmol; 2008; 11(5):327-34. PubMed ID: 19046293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unorthodox ophthalmic preparations on the Ghanaian market: a potential risk for ocular and enteric infections.
    Kyei S; Dogbadze E; Tagoh S; Mwanza E
    Afr Health Sci; 2020 Mar; 20(1):515-523. PubMed ID: 33402940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens.
    Price MO; Price FW; Maclellan D
    J Cataract Refract Surg; 2005 Nov; 31(11):2137-41. PubMed ID: 16412928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
    Yoshida J; Kim A; Pratzer KA; Stark WJ
    J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
    McCulley JP; Caudle D; Aronowicz JD; Shine WE
    Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
    Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
    Donnenfeld ED; Comstock TL; Proksch JW
    J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.
    Williams KK; Shepard AR; Rice RL; McCartney MD; Wax MB; Hiddemen JW
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):517-25. PubMed ID: 18001231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of moxifloxacin as shown in animal and in vitro studies.
    McGee DH; Holt WF; Kastner PR; Rice RL
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ophthalmic infections and their anti-infective challenges.
    Alfonso E; Crider J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Alfonso E
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Blondeau J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of aqueous humor concentrations of fluoroquinolones.
    Scassellati Sforzolini B; Sheets JW; Morris TW
    J Cataract Refract Surg; 2011 Jan; 37(1):217-8. PubMed ID: 21183123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.